Dermatology

This site is intended for healthcare professionals only

Sign in Signup

Medical Jobs
Medical Matrimony
MD Brand Connect
MDTV

Medical News
Health news
Medical Guidelines
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Sign In Register

Sign inRegister

Home
Medical news
Health news
Medical Guidelines
Medical Education
Industry
Case of the Day
Editorial

Dr. Prem Aggarwal

Dr Prem Aggarwal, (DNB Cardiology) is an Cardiologist by profession and also the Co-founder of Medical Dialogues. An avid researcher, he is currently associated with GB Pant Hospital (GIPMER) New Delhi as a PhD Fellow pursuing his research on the topic of Angioplasties on Surgical Rejects

Home
Dr. Prem Aggarwal

Articles By : Dr. Prem Aggarwal

Apixaban a better choice of drug than Rivarobaxan in Atrial Fibrillation- How?

Dr. Nandita Mohan11 Jan 2022 5:15 AM GMT

There is an interesting research which states that apixaban is a much better drug of choice than Rivaroxaban in adults with atrial fibrillation (AF)...

Pharmacological Treatment of Diabetes: ADA 2022 explores beyond metformin as initial therapy

Dr. Prem Aggarwal24 Dec 2021 10:30 AM GMT

New Delhi: Metformin has been the cornerstone of Diabetes management for a long time. However, with the growing research in the field of diabetes and...

Catheter ABlation vs ANtiarrhythmic Drug Therapy in Atrial Fibrillation CABANA trial

ruchika7 Dec 2021 12:03 PM GMT

Radiofrequency ablation for atrial fibrillation (AF) is an 'economically attractive' option compared with drug therapy, according to a new...

Empagliflozin retains benefits in 'True' HFpEF Patients

ruchika3 Dec 2021 12:01 PM GMT

Empagliflozin provides a wide range of benefits in patients with 'true' heart failure and preserved ejection fraction (HFpEF) , meaning an LVEF of 50% ...

Oral PCSK9 inhibitor may significantly reduce LDL C levels: DALLAS, The First Human Trial

Dr. Prem Aggarwal3 Dec 2021 8:37 AM GMT

Low-density lipoprotein (LDL) cholesterol, popularly known as bad cholesterol is major cause of heart disease. LDL C causes build-up of fatty deposits ...

Empagliflozin safe in acute HF, improves 'Clinical Benefit' over time

Dr. Nandita Mohan2 Dec 2021 5:12 AM GMT

Patients with acute heart failure were safely started on empagliflozin a median of 3 days after hospitalization and were 36% more likely to...

Ticagrelor can be discontinued 2-3 days prior to CABG without increasing Bleeding Risk

Dr. Nandita Mohan30 Nov 2021 8:55 AM GMT

According to new randomized data, in patients with ACS, performing CABG within a couple of days after ticagrelor cessation is noninferior to waiting 5 ...

Apolipoprotein B emerges as best lipid predictor for Myocardial Infarction risk

Dr. Nandita Mohan28 Nov 2021 5:00 AM GMT

The risk of myocardial infarction in patients with and without atherosclerosis is best predicted by the number of apolipoprotein B (apoB)-containing...

Guideline update ACC 2021: Diagnostic evaluations and considerations of chest pain

Dr. Prem Aggarwal18 Nov 2021 11:49 AM GMT

The recently issued clinical practice guidelines by ACC for the evaluation and diagnosis of chest pain provide recommendations and algorithms for...

Guideline update ACC 2021: Diagnostic considerations of chest pain

Dr. Prem Aggarwal18 Nov 2021 11:33 AM GMT

The recently issued clinical practice guidelines by ACC for the evaluation and diagnosis of chest pain provide recommendations and algorithms for...

Guideline update ACC 2021: Diagnostic evaluations of chest pain

Dr. Prem Aggarwal18 Nov 2021 11:26 AM GMT

The recently issued clinical practice guidelines by ACC for the evaluation and diagnosis of chest pain provide recommendations and algorithms for...

Guideline update ACC 2021: Acute chest pain

Dr. Prem Aggarwal18 Nov 2021 11:09 AM GMT

The recently issued clinical practice guidelines by ACC for the evaluation and diagnosis of chest pain provide recommendations and algorithms for...

Medical News Today

Health News Today

Powered By: Hocalwire

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok

X